Tvardi Therapeutics, Inc. Operating Income Loss

• Tvardi Therapeutics, Inc. showed an increase of +4.8% in Operating Income Loss from 2024 to 2025.
• This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Tvardi Therapeutics, Inc.'s Operating Income Loss has declined by 328.9%.
• Historical annual values: Fiscal year 2025: -$26.75 million | Fiscal year 2024: -$28.11 million | Fiscal year 2023: -$121.50 million | Fiscal year 2022: -$87.54 million | Fiscal year 2021: -$89.08 million | Fiscal year 2020: $5.39 million | Fiscal year 2019: -$111.68 million | Fiscal year 2018: -$77.38 million | Fiscal year 2017: -$59.49 million | Fiscal year 2016: -$58.40 million | Fiscal year 2015: -$25.19 million | Fiscal year 2014: -$18.07 million | Fiscal year 2013: -$237.0 thousand | Fiscal year 2012: -$6.24 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026